Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

Orally bioavailable LTD4 antagonists from Menarini

Sep. 27, 1996

Glaxo Wellcome prepares a novel class of glycine-site NMDA receptor antagonists

Sep. 27, 1996

Yamanouchi describes AMPA antagonists for stroke

Sep. 27, 1996

Novel antiemetic/gastric prokinetic agent from Dainippon

Sep. 27, 1996

New anxiolytic from SmithKline Beecham

Sep. 27, 1996

Hypocholesterolemic and hypocholesterolemic/antioxidant compounds from Pierre Fabre

Sep. 27, 1996

Immunosuppressant oligopeptide from Italfarmaco

Sep. 27, 1996

Development of COX-2 inhibitors at Searle

Sep. 27, 1996

Ciba characterizes another novel HIV protease inhibitor

Sep. 27, 1996

Novel class of HIV protease inhibitors with improved activity

Sep. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.